Novel potential targets for function-promoting therapies: orphan nuclear receptors, anti-inflammatory drugs, troponin activators, mas receptor agonists, and urolithin A

Authors: DIOH, WALY - Biophytis; NARKAR, VIHANG - University Of Texas Health Science Center; SINGH, ANURAG - Amazentiz; MALIK, ANDY - Cytokinetics, Inc; FERRUCCI, LUIGI - National Institute On Aging (NIA, NIH); TOURETTE, CENDRINE - Biophytis; MARIANI, JEAN - Biophytis; VANMAANEN, ROB - Biophytis; FIELDING, ROGER - Jean Mayer Human Nutrition Research Center On Aging At Tufts University

Submitted to: Journal of Gerontology Medical Science
Publication Type: Review Article
Publication Acceptance Date: 1/31/2023
Publication Date: 6/16/2023
Citation: Dioh, W., Narkar, V., Singh, A., Malik, A., Ferrucci, L., Tourette, C., Mariani, J., Vanmaanen, R., Fielding, R.A. 2023. Novel potential targets for function-promoting therapies: orphan nuclear receptors, anti-inflammatory drugs, troponin activators, mas receptor agonists, and urolithin A. Journal of Gerontology Medical Science. https://doi.org/10.1093/gerona/glad072.
DOI: https://doi.org/10.1093/gerona/glad072

Interpretive Summary:

Technical Abstract: Background: In recent years, several new classes of therapies have been investigated with their potential for restoring or improving physical functioning in older adults. These have included: Mas receptor activators, regulators of mitophagy, skeletal muscle troponin activators, anti-inflammatory compounds, and targets of orphan nuclear receptors. Methods: Review of literature. Results: The present article summarizes recent developments of the function promoting effects of these exciting new compounds and shares relevant pre-clinical and clinical data related to their safety and efficacy. Conclusions: The development of novel compounds in this area and expanding and likely will need to the advent of new treatment paradigm for age-associated mobility loss and disability.